Related Experiment Video
Updated: Jul 17, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells
Eleonora Petrucci1, Luca Pasquini, Alessia Petronelli
1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Objectives:
Ovarian cancer remains a leading cause of death in women and development of new therapies is essential. Second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis. We have explored the proapoptotic activity of a small molecule mimic of Smac/DIABLO on ovarian cancer cell lines (A2780 cells and its chemoresistant derivatives A2780/ADR and A2780/DDP), cancer cell lines and in primary ovarian cancer cells.
Methods:
The effects of a small molecule mimic of Smac/DIABLO on ovarian cancer cell lines and primary ovarian cancer cells were determined by cell proliferation, apoptosis and biochemical assays.
Results:
This compound added alone elicited only a weak proapoptotic effect; however, it strongly synergizes with tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or agonistic TRAILR2 antibody (Lexatumumab) in inducing apoptosis of ovarian cancer cells.
Conclusions:
These observations suggest that small molecule mimic of Smac/DIABLO could be useful for the development of experimental strategies aiming to treat ovarian cancer. Interestingly, in addition to its well known proapoptotic effects, Smac/DIABLO elicited a significant increase of pro-caspase-3 levels.
Insights
A novel small molecule mimic of Second mitochondria derived activator of caspase (Smac/DIABLO) shows potential in treating ovarian cancer. It synergizes with TRAIL or Lexatumumab to enhance apoptosis in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ovarian cancer is a significant cause of mortality in women, necessitating novel therapeutic approaches.
- Second mitochondria derived activator of caspase (Smac/DIABLO) is known to sensitize cells to apoptosis.
- Investigating Smac/DIABLO mimetics offers a promising avenue for ovarian cancer treatment.
Purpose of the Study:
- To evaluate the proapoptotic activity of a small molecule Smac/DIABLO mimic.
- To assess its efficacy on ovarian cancer cell lines, including chemoresistant variants, and primary ovarian cancer cells.
Main Methods:
- Cell proliferation assays.
- Apoptosis assays.
- Biochemical assays were employed to determine the effects of the Smac/DIABLO mimic.
Main Results:
- The Smac/DIABLO mimic alone demonstrated a modest proapoptotic effect.
- Significant synergy was observed when combined with tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or Lexatumumab in inducing ovarian cancer cell apoptosis.
- Increased pro-caspase-3 levels were noted, alongside proapoptotic effects.
Conclusions:
- Small molecule Smac/DIABLO mimics hold promise for experimental ovarian cancer treatment strategies.
- The synergistic effect with TRAIL or Lexatumumab enhances therapeutic potential.
- Further research into Smac/DIABLO pathways could lead to improved ovarian cancer therapies.
